 |
|
|
| |
HIGH EFFICACY OF ABT-493 AND ABT-530 IN HCV GENOTYPE 1-INFECTED PATIENTS WHO HAVE FAILED DIRECT-ACTING ANTIVIRAL-CONTAINING REGIMENS: THE MAGELLAN-I STUDY
|
| |
| |
Reported by Jules Levin
51st Annual Meeting of the European Association for the Study of the Liver
Barcelona, Spain, 15 April 2016
Fred Poordad1, Stuart C Gordon2, Armen Asatryan3, Franco Felizarta4, Robert W Reindollar5, Charles Landis6, Michael W Fried7, David E Bernstein8, Teresa I Ng3, Chih-Wei Lin3, Ran Liu3, Jens Kort3, Federico J Mensa3
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2Henry Ford Health System, Detroit, MI, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Private practice, Bakersfield, CA, USA; 5Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, NC, USA; 7University of North Carolina at Chapel Hill, UNC Liver Center, Chapel Hill, NC, USA; 8North Shore University Hospital, Manhasset, NY, USA
|
| |
|
|
|
|
|
